Science and Research

TROPION-Lung08 / DS1062-A-U304: A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-Small Cell Lung Cancer without Actionable Genomic Alterations.

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC) of non-squamous histology.

Study details
Study-ID: NCT05215340, 2021-002555-10
Study-ID: NCT05215340, 2021-002555-10
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL discovery-based, DZL on steering board
DZL Role: DZL discovery-based, DZL on steering board
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: ARCN, CPC-M
DZL Participating Sites: ARCN, CPC-M
Start Date: 04.03.2022
Completion Date: 30.04.2028
Status: Recruiting
Status: Recruiting
DZL discovery-based, DZL on steering board
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.